Pharmacogenetics‐Based New Therapeutic Concepts

Roots, Ivar; Gerloff, Thomas; Meisel, Christian; Kirchheiner, Julia; Goldammer, Mark; Kaiser, Rolf; Laschinski, Gabriele; Brockmöller, Jürgen; Cascorbi, Ingolf; Kleeberg, Ullrich; Hildebrandt, Alfred G.

doi:10.1081/dmr-200033458

Cited by 33Pharmacogenetics and Drug MetabolismNutrition, Genetics, and DiseaseGenetic Associations and Epidemiology

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Pharmacogenetics‐Based New Therapeutic Concepts

Roots, Ivar, Gerloff, Thomas, Meisel, Christian, Kirchheiner, Julia, Goldammer, Mark, Kaiser, Rolf, Laschinski, Gabriele, Brockmöller, Jürgen, Cascorbi, Ingolf, Kleeberg, Ullrich, Hildebrandt, Alfred G.·2004·Drug Metabolism Reviews

DOI 10.1081/dmr-200033458

Open this paper in CoChat — free account

Abstract

Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Pharmacogenetics adds a considerable amount of stringency to the doctor's therapeutic approach. Today, it is the relationship between dosage requirements and genetic variations in drug metabolizing enzymes like cytochrome P450 (CYP) 2D6 and CYP2C19, or in drug transporters like p-glycoprotein, that is substantiated best. A standard dose will bring about more adverse effects than usual if enzymatic activity is lacking or feeble. Sometimes, however, therapeutic response might be better due to higher concentrations: proton pump inhibitors for eradication of Helicobacter pylori are more efficacious in carriers of a deficient CYP2C19 variant. The drug's interaction with its target (e.g. receptor) also depends on genetic factors. In some cases genetic tests can help distinguish between responders and non-responders of a specific drug treatment. The first pharmacogenetic tests are already on the market.

Integrity signals

Registry

Crossref · 10.1081/dmr-200033458

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The prediction of human CLH by IVIVE is generally limited by inter-individual variability, most likely due to drug metabolizing enzymes.
“The prediction of human CLH by IVIVE is generally limited by IIV, most likely due to drug metabolizing enzymes [74].”
From Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling (2019) · cites this paper as [74]

Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366
Self-citation
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.
Cordon‐Cardo, C., O’Brien, J. P., Boccia, J. P., Casals, D., Bertino, J. R., & Melamed, M. R. (1990) · Journal of Histochemistry & Cytochemistry · doi:10.1177/38.9.1974900 · Cited by 1,062
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
Self-citation
Complex promoter and coding region β 2 -adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
Drysdale, C. M., McGraw, D. W., Stack, C. B., Stephens, J. C., Judson, R., Nandabalan, K., Arnold, K., Ruaño, G., & Liggett, S. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10483 · Cited by 959
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 728
Self-citation
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver
Kullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K. E., Meier, P. J., & Hagenbuch, B. (2001) · Gastroenterology · doi:10.1053/gast.2001.21176 · Cited by 718
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07276-8 · Cited by 658
Molecular Identification and Characterization of Novel Members of the Human Organic Anion Transporter (OATP) Family
Tamai, I., Nezu, J., Uchino, H., Sai, Y., Oku, A., Shimane, M., & Tsuji, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2922 · Cited by 643
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B. C., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V. G., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 638
Polymorphisms in OATP-C
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 625
The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis
Kuivenhoven, J. A., Jukema, J. W., Zwinderman, A. H., de Knijff, P., McPherson, R., Bruschke, A. V. G., Lie, K. I., & Kastelein, J. J. P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380203 · Cited by 623
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050585397 · Cited by 599
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.
Poirier, J., Delisle, M.-C., Quirion, R., Aubert, I., Farlow, M. R., Lahiri, D. K., Hui, S. L., Bertrand, P., Nalbantoglu, J. N., & Gilfix, B. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12260 · Cited by 593
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetković, M., Leake, B. F., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 592
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
Drazen, J. M., Yandava, C., Dubé, L. M., Szczerbak, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N. J., Silverman, E. S., Katz, D. A., et al. (1999) · Nature Genetics · doi:10.1038/9680 · Cited by 561
The Effect of Polymorphisms of the β2-Adrenergic Receptor on the Response to Regular Use of Albuterol in Asthma
Israel, E., Drazen, J. M., Liggett, S. B., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., Cooper, D. M. L., Fahy, J. V., Fish, J. E., Ford, J. G., et al. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.1.9907092 · Cited by 549
Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension
Cusi, D., Barlassina, C., Azzani, T., Casari, G., Citterio, L., Devoto, M., Glorioso, N., Lanzani, C. L., Manunta, P., Righetti, M., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01029-5 · Cited by 537
Choroid plexus epithelial expression of MDR 1 P glycoprotein and multidrug resistance-associated protein contribute to the blood–cerebrospinal-fluid drug-permeability barrier
Rao, V. V., Dahlheimer, J. L., Bardgett, M. E., Snyder, A. Z., Finch, R. A., Sartorelli, A. C., & Piwnica-Worms, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3900 · Cited by 531
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
P‐glycoprotein: multidrug‐resistance and a superfamily of membrane‐associated transport proteins
Juranka, P. F., Zastawny, R. L., & Ling, V. W. T. (1989) · The FASEB Journal · doi:10.1096/fasebj.3.14.2574119 · Cited by 509
A common polymorphism associated with antibiotic-induced cardiac arrhythmia
Sesti, F., Abbott, G. W., Wei, J., Murray, K. T., Saksena, S. V., Schwartz, P. J., Priori, S. G., Roden, D. M., George, A. L., & Goldstein, S. A. N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180223197 · Cited by 479
Role of transport proteins in drug absorption, distribution and excretion
Ayrton, A. D., & Morgan, P. M. (2001) · Xenobiotica · doi:10.1080/00498250110060969 · Cited by 426
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages
Kirchheiner, J., Brøsen, K., Dahl, M., Gram, L. F., Kasper, S. F., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Self-citation
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
Hitzl, M., Drescher, S., van der Kuip, H., Schäffeler, E., Fischer, J., Schwab, M. G., Eichelbaum, M., & Fromm, M. F. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00003 · Cited by 370
The Effect of Common Polymorphisms of the β2-Adrenergic Receptor on Agonist-Mediated Vascular Desensitization
Dishy, V., Sofowora, G. G., Xie, H., Kim, R. B., Byrne, D. W., Stein, C. M., & Wood, A. J. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010819 · Cited by 363
Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver
Meier, P. J., Eckhardt, U., Schroeder, A., Hagenbuch, B., & Stieger, B. (1997) · Hepatology · doi:10.1002/hep.510260641 · Cited by 359
Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00006 · Cited by 333
Determination of drug metabolizing enzymes in needle biopsies of human liver
Schoene, B., Fleischmann, R., Remmer, H., & Oldershausen, H.-F. V. (1972) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562499 · Cited by 326
MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects
Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., Hirai, M., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1012244520615 · Cited by 322
Genetic Polymorphisms of Human Organic Anion Transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele Frequencies in the Japanese Population and Functional Analysis
Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J., Sai, Y., Tsuji, A., & Yokoi, T. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.2.804 · Cited by 319
Platelet GP IIIa Pl A Polymorphisms Display Different Sensitivities to Agonists
Michelson, A. D., Furman, M. I., Goldschmidt‐Clermont, P. J., Mascelli, M. A., Hendrix, C. W., Coleman, L., Hamlington, J. D., Barnard, M. R., Kickler, T. S., Christie, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.9.1013 · Cited by 306
Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene
Johne, A., Köpke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M. F., Brinkmann, U., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129196 · Cited by 305
Self-citation
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 292
Role of P-Glycoprotein in Drug Disposition
Tanigawara, Y. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200002000-00029 · Cited by 259
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
Furuta, T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113959 · Cited by 254
Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes
Kaiser, R., Sezer, O., Papies, A., Bauer, S., Schelenz, C., Tremblay, P., Possinger, K., Roots, I., & Brockmöller, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.064 · Cited by 251
Self-citation
Impact of genetic polymorphisms of the β -adrenergic receptor on albuterol bronchodilator pharmacodynamics
LIMA, J., Thomason, D. B., MOHAMED, M., EBERLE, L., Self, T. H., & Johnson, J. A. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70071-8 · Cited by 250
Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?
Nebert, D. W. (1997) · PubMed · Cited by 235
The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment
Brockmöller, J., Kirchheiner, J., Schmider, J., Walter, S., Sachse, C., Müller-Oerlinghausen, B., & Roots, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127494 · Cited by 204
Self-citation
The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol
Siegmund, W., Ludwig, K., Gießmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kroemer, H. K., & Cascorbi, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127739 · Cited by 200
Self-citation
Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients
Tremblay, P., Kaiser, R., Sezer, O., Rösler, N., Schelenz, C., Possinger, K., Roots, I., & Brockmöller, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.164 · Cited by 157
Self-citation
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole
Furuta, T., Shirai, N., Watanabe, F., Honda, S., Takeuchi, K., Iida, T., Sato, Y., Kajimura, M., Futami, H., Takayanagi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127637 · Cited by 153
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males
Gerloff, T., Schaefer, M., Johne, A., Oselin, K., Meisel, C., Cascorbi, I., & Roots, I. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01691.x · Cited by 151
Self-citation
FAMILIAL INCIDENCE OF LOW PSEUDOCHOLINESTERASE LEVEL
KALOW, W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)92065-7 · Cited by 143
A Naturally Occurring Mutation in the SLC21A6Gene Causing Impaired Membrane Localization of the Hepatocyte Uptake Transporter
Michalski, C. W., Cui, Y., Nies, A. T., Nussler, A. K., Neuhaus, P., Zanger, U. M., Klein, K., Eichelbaum, M. F., KEPPLER, D. O. R., & König, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207735200 · Cited by 140
Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin
Furuta, T., Shirai, N., Takashima, M., Fang, X., Hanai, H., Nakagawa, K., Sugimura, H., Ohashi, K., & Ishizaki, T. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00009 · Cited by 134
PlA2 polymorphism and efficacy of aspirin
Cooke, G. E., Bray, P. F., Hamlington, J. D., Pham, D., & Goldschmidt‐Clermont, P. J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79320-x · Cited by 131
Membrane transporters
Lee, V. H. L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00163-9 · Cited by 129
l -Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism
Kaiser, R., Höfer, A., Grapengiesser, A., Gasser, T., Kupsch, A. R., Roots, I., & Brockmöller, J. (2003) · Neurology · doi:10.1212/01.wnl.0000068009.32067.a1 · Cited by 126
Self-citation
The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man
Paulusma, C. C., & Elferink, R. P. J. O. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050127 · Cited by 111
Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview
Kruijtzer, C. M. F., Beijnen, J. H., & Schellens, J. H. M. (2002) · The Oncologist · doi:10.1634/theoncologist.7-6-516 · Cited by 110
Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment
Brockmöller, J., Kirchheiner, J., Meisel, C., & Roots, I. (2000) · Pharmacogenomics · doi:10.1517/14622416.1.2.125 · Cited by 106
Self-citation
Effect of Polymorphism of the β2-Adrenergic Receptor on Response to Regular Use of Albuterol in Asthma
Israel, E., Drazen, J. M., Liggett, S. B., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., Cooper, D. M. L., Fahy, J. V., Fish, J. E., Ford, J. G., et al. (2001) · International Archives of Allergy and Immunology · doi:10.1159/000053705 · Cited by 103
ACE (I/D) Genotype as a Predictor of the Magnitude and Duration of the Response to an ACE Inhibitor Drug (Enalaprilat) in Humans
Ueda, S., Meredith, P., Morton, J. J., Connell, J., & Elliott, H. L. (1998) · Circulation · doi:10.1161/01.cir.98.20.2148 · Cited by 103
Pharmacogenetic applications of the Human Genome project
Liggett, S. B. (2001) · Nature Medicine · doi:10.1038/85411 · Cited by 92
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan
Dojo, M., Azuma, T., Saito, T., Ohtani, M., Muramatsu, A., & Kuriyama, M. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80043-8 · Cited by 79
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection
Take, S., Mizuno, M., Ishiki, K., Nagahara, Y., Yoshida, T., Inaba, T., Yamamoto, K., Okada, H., Yokota, K., Oguma, K., et al. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00713-5 · Cited by 76
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype
Inaba, T., Mizuno, M., Kawai, K., Yokota, K., Oguma, K., Miyoshi, M., Take, S., Okada, H., & Tsuji, T. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02790.x · Cited by 76
�ber die Erbbedingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menschen (Untersuchungen an eineiigen und zweieiigen Zwillingen)
B�nicke, R., & Lisboa, B. P. (1957) · Die Naturwissenschaften · doi:10.1007/bf00621632 · Cited by 76
Induction of the Unspecific Microsomal Hydroxylase in the Human Liver
Remmer, H., Schoene, B., Fleischmann, R., & Held, H. (2015) · KARGER eBooks · doi:10.1159/000394816 · Cited by 75
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan
Miki, I., Aoyama, N., Sakai, T., Shirasaka, D., Wambura, C. M., Maekawa, S., Kuroda, K., Tamura, T., Kita, T., Sakaeda, T., et al. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200301000-00006 · Cited by 72
The Modified Dipeptide, Enalapril, An Angiotensin–Converting Enzyme Inhibitor, Is Transported by the Rat Liver Organic Anion Transport Protein
Pang, K. S., Wang, P. J., Chung, A. Y., & Wolkoff, A. W. (1998) · Hepatology · doi:10.1002/hep.510280524 · Cited by 69
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism
Miyoshi, M., Mizuno, M., Ishiki, K., Nagahara, Y., Maga, T., Torigoe, T., Nasu, J., Okada, H., Yokota, K., Oguma, K., et al. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02526.x · Cited by 68
Reduced inhibition by abciximab in platelets with the PlA2 polymorphism
Wheeler, G. L., Braden, G. A., Bray, P. F., Marciniak, S. J., Mascelli, M. A., & Sane, D. C. (2002) · American Heart Journal · doi:10.1067/mhj.2002.119763 · Cited by 68
Die Beschleunigung des Evipanabbaues unter der Wirkung von Barbituraten
Remmer, H. (1958) · Die Naturwissenschaften · doi:10.1007/bf00621338 · Cited by 68
Transport of Temocaprilat into Rat Hepatocytes: Role of Organic Anion Transporting Polypeptide
Ishizuka, H., Konno, K., Naganuma, H., Nishimura, K., Kouzuki, H., Suzuki, H., Stieger, B., Meier, P. J., & Sugiyama, Y. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37760-2 · Cited by 67
Implications of pharmacogenetics for individualizing drug treatment and for study design
Meisel, C., Gerloff, T., Kirchheiner, J., Mrozikiewicz, P. M., Niewiński, P., Brockmöller, J., & Roots, I. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0417-4 · Cited by 65
Self-citation
Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists
Kaiser, R., Tremblay, P., Sezer, O., Possinger, K., Roots, I., & ller, J. R. B. (2004) · Pharmacogenetics · doi:10.1097/00008571-200405000-00001 · Cited by 65
Self-citation
Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics
Kirchheiner, J., Müller, G., Meineke, I., Wernecke, K., Roots, I., & Brockmöller, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000088909.24613.92 · Cited by 57
Self-citation
Nonlinear Kinetics After High–Dose Omeprazole Caused by Saturation of Genetically Variable Cyp2c19
Rost, K. L., & Roots, I. (1996) · Hepatology · doi:10.1002/hep.510230628 · Cited by 40
Self-citation
How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport
Meisel, C., Roots, I., Cascorbi, I., Brinkmann, U., & Brockmöller, J. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.126 · Cited by 39
Self-citation
Die Aktivierung der Entgiftung in den Lebermikrosomen w�hrend der Gew�hnung
Remmer, H., & Alsleben, B. (1958) · Journal of Molecular Medicine · doi:10.1007/bf01480679 · Cited by 39
Lafutidine, a Novel Histamine H2‐Receptor Antagonist, vs. Lansoprazole in Combination with Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori
Isomoto, H., Inoue, K., Furusu, H., Nishiyama, H., Shikuwa, S., Omagari, K., Mizuta, Y., Murase, K., Murata, I., & Kohno, S. (2003) · Helicobacter · doi:10.1046/j.1523-5378.2003.00131.x · Cited by 28
Pharmacogenomics of Diuretic Drugs: Data on Rare Monogenic Disorders and on Polymorphisms and Requirements for Further Research
Vormfelde, S. V., Burckhardt, G., Zirk, A., Wojnowski, L., & Brockmöller, J. (2003) · Pharmacogenomics · doi:10.1517/phgs.4.6.701.22817 · Cited by 23
Self-citation
Dyspeptic symptoms associated with Helicobacter pylori infection are influenced by strain and host specific factors
Treiber, G., Schwabe, M., Ammon, S., Walker, S., Klotz, U. E., & Malfertheiner, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01751.x · Cited by 16
Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism
Lutz, M., Schwab, M. G., Griese, E., Marx, C., Müller-Oerlinghausen, B., Schönhöfer, P. S., Meisner, C., Gleiter, C. H., Eichelbaum, M. F., & Mörike, K. (2002) · Pharmacogenetics · doi:10.1097/00008571-200201000-00010 · Cited by 15
Pharmakogenetik als Basis neuer Therapiekonzepte
Kirchheiner, J., Meisel, C., Goldammer, M., Gerloff, T., Kaiser, R., & Roots, I. (2003) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-003-0694-2 · Cited by 5
Self-citation

Flagged first, then by citations

Research works printed but not linked: 5

Cvetkovic M., 1999, Drug Metab. Dispos., 27, 866
Ishizuka H., 1998, J. Pharmacol. Exp. Ther., 287, 37
Remmer H., 1973, Drug Metab. Disposition, 1, 224
Sachse C., 1997, Am. J. Hum. Genet., 60, 265
Take S., 2003, Am. J. Gastroenterol., 98, 2403

Sorted by citations

Can Pharmacogenetics Help Rescue Drugs Withdrawn from the Market?
Shah, R. R. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.889 · Cited by 179
The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis
Padol, S., Yuan, Y., Thabane, M. E., Padol, I. T., & Hunt, R. H. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00717.x · Cited by 159
Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents
Murray, M. T. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.7.0001 · Cited by 124
Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease)
Roses, A. D., Saunders, A. M., Huang, Y., Strum, J. C., Weisgraber, K. H., & Mahley, R. W. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500397 · Cited by 109
Applications of AmpliChip??? CYP450
Jain, K. K. (2005) · Molecular Diagnosis · doi:10.2165/00066982-200509030-00002 · Cited by 88
Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling
Choi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040168 · Cited by 79
“The prediction of human CLH by IVIVE is generally limited by IIV, most likely due to drug metabolizing enzymes [74].”
Background
The genetic influence on bone susceptibility to fluoride
Mousny, M., Banse, X., Wise, L., Everett, E. T., Hancock, R. G. V., Vieth, R., Devogelaer, J., & Grynpas, M. D. (2006) · Bone · doi:10.1016/j.bone.2006.06.006 · Cited by 65
Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine
Ramsey, L. B., Prows, C. A., Zhang, K., Saldaña, S. N., Sorter, M. T., Pestian, J. P., WENSTRUP, R. J., Vinks, A. A. T. M. M., & Glauser, T. A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1165 · Cited by 57
Genetic diversity and new therapeutic concepts
Shastry, B. S. (2005) · Journal of Human Genetics · doi:10.1007/s10038-005-0264-6 · Cited by 48
CYP2D6 gene test in psychiatric patients and healthy volunteers
Rasmussen, J. O., Christensen, M., Svendsen, J. M., Skausig, O. B., Hansen, E., & Nielsen, K. A. (2006) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510500469702 · Cited by 28
Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: the convolution continues
Turman, C. M., Hatley, J. M., Ryder, D. J., Ravindranath, V., & Strobel, H. W. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.3.399 · Cited by 20
Personalizing Drug Selection Using Advanced Clinical Decision Support
Pestian, J. P., Spencer, M., Matykiewicz, P., Zhang, K., Vinks, S., & Glauser, T. A. (2009) · Biomedical Informatics Insights · doi:10.4137/bii.s2506 · Cited by 20
Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures
Lee, S. M., Chung, J., Lee, Y., Park, M. S., Namgung, R., Park, K. I., & Lee, C. (2012) · Archives of Disease in Childhood · doi:10.1136/archdischild-2011-300538 · Cited by 17
Contraindication labelling changes in the United States and Germany
Garbe, E., & Andersohn, F. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0229-5 · Cited by 13
Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes™
Nielsen, K. A., Hansen, E., & Gille, S. (2007) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601039982 · Cited by 8
Genotype and Phenotype Relationship in Drug Metabolism
Roots, I., Laschinski, G., Arjomand-Nahad, F., Kirchheiner, J., Schwarz, D., Brockmöller, J., Cascorbi, I., & Gerloff, T. (2007) · Springer eBooks · doi:10.1007/978-3-540-49529-1_6 · Cited by 8
Self-citation
Race as a variable in pharmacogenomics science: from empirical ethics to publication standards
Özdemir, V., Graham, J., & Godard, B. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830a48f3 · Cited by 7
Pharmakogenetik und Pharmakogenomik
Roots, I., Laschinski, G., & Meyer, U. (2008) · Springer eBooks · doi:10.1007/978-3-540-69414-4_13 · Cited by 6
Self-citation
Kinetics and dosing
Tisserand, R., & Young, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-443-06241-4.00004-7 · Cited by 6
Glucoproteína P e infección por el virus de la inmunodeficiencia humana
Peralta, G., Sánchez, M. B., Echevarría, S., Valdizán, E. M., & Armijo, J. A. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13116752 · Cited by 6
Pharmacology, Drug Efficacy, and the Individual
Hildebrandt, A. G. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033500 · Cited by 5
Self-citation
Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy
Salamone, S., Spirito, S., Simmaco, M., Unger, M., Preißner, S., Gohlke, B.-O., Eckert, A. P., & Preißner, R. (2022) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s368606 · Cited by 4
Farmacogenética de inibidores seletivos de recaptação de serotonina: uma revisão
Silva, D. K., & de Andrade, F. M. (2008) · Revista de Psiquiatria do Rio Grande do Sul · doi:10.1590/s0101-81082008000200004 · Cited by 4
Single nucleotide polymorphisms in the development of osteomyelitis and prosthetic joint infection: a narrative review
Zhou, J., Liu, Z., Zhong, H.-F., Liu, G., Ding, M.-C., Zhang, Y. L., Yu, B., & Jiang, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444469 · Cited by 3
The Pharmacogenetics of Cytochrome P-450 and its Effect on Drug Metabolism
BEREWELA, D. A. M. (2020) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v10i5-s.4473 · Cited by 2
Intelligent Biometric System Using Soft Computing Tools
Shukla, A., Tiwari, R., & Rathore, C. P. (2010) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-61692-004-3.ch014 · Cited by 1
How the Monoamine Transporter Garden Grows
Ruoho, A. E. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014951
A Comparison of the Effect of Omeprazole and Rabeprazole on Clozapine Serum Concentrations
Jabarizadekivi, N. (2007) · The Sydney eScholarship Repository (The University of Sydney)
Pharmacogenetics/Pharmacogenomics
Lou, X. J., Altman, R. B., & Klein, T. E. (2007) · Wiley eBooks · doi:10.1002/9783527619368.ch39
Pharmakogenetik
Meisel, C., & Roots, I. (2007) · Springer eBooks · doi:10.1007/978-3-540-48554-4_3
Self-citation
Pharmakogenetik
Meisel, C., & Roots, I. (2006) · Springer eBooks · doi:10.1007/3-540-29812-6_7
Self-citation
References
(2013) · Elsevier eBooks · doi:10.1016/b978-0-443-06241-4.09996-3

Authors: Roots, I., Gerloff, T., Meisel, C., Kirchheiner, J., Goldammer, M., Kaiser, R., Laschinski, G., Brockmöller, J., Cascorbi, I., Kleeberg, U., & Hildebrandt, A. G.
Affiliations: Humboldt-Universität zu Berlin (DE)
Universitätsmedizin Göttingen (DE)
Christian-Albrechts-Universität zu Kiel (DE)
Robert Koch Institute (DE)
ORCID: Kaiser, Rolf
Brockmöller, Jürgen
Cascorbi, Ingolf
Venue: Drug Metabolism Reviews
Publisher: Informa UK Limited
Published: 2004-01
Volume: 36
Issue: 3-4
Pages: 617-638
ISSN: 0360-2532 (ISSN-L)
1097-9883
DOI: 10.1081/dmr-200033458
OpenAlex: W2138194001
Cited by: 33
References: 79
Citations by year: 2024: 1 · 2022: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2013: 2 · 2012: 1
FWCI: 4.90
Type: journal article
Language: en
Open access: closed
Locations: Drug Metabolism Reviews (publishedVersion)
PubMed (publishedVersion)
GRO (submittedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords: pharmacogenetics, personalized medicine, drug response, genetic variation, CYP2D6, CYP2C19, P-glycoprotein, drug transporters, drug metabolism, adverse drug reactions, proton pump inhibitors, Helicobacter pylori eradication, genetic testing, drug response prediction
MeSH terms: Animals, Cytochrome P-450 Enzyme System, Pharmaceutical Preparations, Humans, Pharmacogenetics, Genetic Variation, Xenobiotics, Polymorphism, Single Nucleotide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacogenetics‐Based New Therapeutic Concepts

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks